^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    PD1 inhibitor

    Related drugs:
    17h
    Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma (clinicaltrials.gov)
    P1, N=31, Active, not recruiting, City of Hope Medical Center | Suspended --> Active, not recruiting
    Enrollment closed
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    18h
    Prospective, Open-label, Multi-cohort Study of Becotatug Vedotin With Tislelizumab and Chemotherapy in Esophageal Squamous Cell Carcinoma - Phase 2 (clinicaltrials.gov)
    P2, N=93, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P2 trial
    |
    cisplatin • Tevimbra (tislelizumab-jsgr) • Meiyouheng (becotatug vedotin)
    19h
    A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer. (clinicaltrials.gov)
    P1, N=56, Active, not recruiting, M.D. Anderson Cancer Center | Trial primary completion date: Jan 2026 --> Jan 2028
    Trial primary completion date
    |
    STK11 (Serine/threonine kinase 11)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR exon 20 mutation
    |
    Libtayo (cemiplimab-rwlc) • Kevzara (sarilumab)
    19h
    A Phase II Single-arm Clinical Study in the Treatment of Locally Advanced Esophageal Cancer After Failed Neoadjuvant Chemoimmunotherapy (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
    New P2 trial
    |
    Qibeian (iparomlimab/tuvonralimab)
    19h
    Recombinant Humanized Anti-CD47 / PD-1 Bifunctional Antibody HX009 Injection in the Treatment of Advanced Solid Tumors (clinicaltrials.gov)
    P2, N=20, Completed, Hangzhou Hanx Biopharmaceuticals, Ltd. | Active, not recruiting --> Completed | N=210 --> 20
    Trial completion • Enrollment change
    |
    PD-L1 (Programmed death ligand 1)
    |
    HX-009
    20h
    Vebrekotuzumab ± Anti-PD-1 in Pretreated Advanced ESCC (clinicaltrials.gov)
    P2, N=104, Suspended, Fudan University | Recruiting --> Suspended
    Trial suspension
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR expression • EGFR positive
    |
    Keytruda (pembrolizumab)
    20h
    SPARC-1: A Study of Combination Spartalizumab and Canakinumab in Patients With Localized Clear Cell Renal Cell Carcinoma (clinicaltrials.gov)
    P1, N=17, Completed, Columbia University | Active, not recruiting --> Completed
    Trial completion
    |
    CD4 (CD4 Molecule)
    |
    spartalizumab (PDR001) • Ilaris (canakinumab)
    20h
    Phase II Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Albumin-Bound Paclitaxel and Lenvatinib as Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer (clinicaltrials.gov)
    P2, N=40, Recruiting, Sun Yat-sen University
    New P2 trial
    |
    Lenvima (lenvatinib) • albumin-bound paclitaxel • Qibeian (iparomlimab/tuvonralimab)
    22h
    17000139BLC2002: A Phase 2, Open-Label, Multi-Center, Randomized Study of TAR-200 in Combination with Cetrelimab and Cetrelimab Alone in Participants with Muscle-Invasive Urothelial Carcinoma of the Bladder who are Scheduled for Radical Cystectomy and are Ineligible for or Refusing Platinum-Based Neoadjuvant Chemotherapy (2023-507189-17-00)
    P1/2, N=89, Completed, Janssen - Cilag International | Active, not recruiting --> Completed
    Trial completion
    |
    cetrelimab (JNJ-63723283) • Inlexzo (gemcitabine intravesical system)
    22h
    ANTARES: Agnostic Therapy in Rare Solid Tumors (clinicaltrials.gov)
    P2, N=28, Recruiting, Instituto do Cancer do Estado de São Paulo | Active, not recruiting --> Recruiting
    Enrollment open • IO biomarker • Pan tumor
    |
    FH (Fumarate Hydratase) • MITF (Melanocyte Inducing Transcription Factor)
    |
    Opdivo (nivolumab)
    22h
    A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery (clinicaltrials.gov)
    P2, N=195, Recruiting, Regeneron Pharmaceuticals | Active, not recruiting --> Recruiting
    Enrollment open
    |
    PD-L1 (Programmed death ligand 1)
    |
    cisplatin • carboplatin • paclitaxel • pemetrexed • Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767)
    22h
    HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA (clinicaltrials.gov)
    P1, N=32, Completed, Baylor College of Medicine | Active, not recruiting --> Completed | Trial completion date: Oct 2033 --> Jan 2026
    Trial completion • Trial completion date
    |
    Opdivo (nivolumab) • cyclophosphamide • fludarabine IV